Neutral impactStocks
Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Piramal Pharma on 20 July
livemint.com 20 hrs ago·20 Jul 2026, 4:13 am
Stocks livemint.com
Dharmesh Shah, a senior executive at ICICI Securities, has recommended buying shares of Piramal Pharma. This comes as a strategic move to capitalize on the company's ongoing efforts to strengthen its global pharmaceutical business. Shah believes the current valuation offers a good entry point for investors looking to benefit from the company's long-term growth potential in the specialty and generic drug markets.
For investors, this endorsement highlights Piramal Pharma's strong position in the healthcare sector. The company is actively working on expanding its international footprint and enhancing its product portfolio. This focus on innovation and global expansion is expected to drive revenue growth in the coming years, making it a stock worth watching for those interested in the healthcare industry.
Investors should keep an eye on the company's quarterly earnings reports and its progress in international acquisitions. Any positive updates on these fronts could further support the stock's performance. It is important to remember that stock market investments carry risks, and investors should do their own research before making any decisions.
Key takeaways
- Category: Stocks.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.
